Resveratrol solid lipid microparticles as dry powder formulation for nasal delivery, characterization and in vitro deposition study

References

• Alexander NS, Hatch N, Zhang S, Skinner D, Fortenberry J, Sorscher EJ, Woodworth BA. Resveratrol has salutary effects on mucociliary transport and inflammation in sinonasal epithelium. Laryngoscope, 2011;121:1313–19.
   PubMed Web of Science ®Google Scholar
• Allen DB. Systemic effects of intranasal steroids: An endocrinologist's perspective. J Allergy Clin Immunol, 2000;106:S179–90.
   PubMed Web of Science ®Google Scholar
• Alhalaweh A, Andersson S, Velaga SP. Preparation of zolmitriptan-chitosan microparticles by spray drying for nasal delivery. Eur J Pharm Sci, 2009;38:206–14.
   PubMed Web of Science ®Google Scholar
• Amidi M, Romeijn SG, Borchard G, Junginger HE, Hennink WE, Jiskoot W. Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system. J Control Release, 2006;111:107–16.
   PubMed Web of Science ®Google Scholar
• Amri A, Chaumeil JC, Sfar S, Charrueau C. Administration of resveratrol: What formulation solutions to bioavailability limitations? J Control Release, 2012;158:182–93.
   PubMed Web of Science ®Google Scholar
• Bernstein JA, Smith AM. 2014. Physiology and immune responses of the nose and sinuses. In: Chang CC, Incaudo GA, Gershwin ME, eds. Diseases of the sinuses. New York: Springer, pp. 52–3.
   Google Scholar
• Bott RF, Oliveira WP. Storage conditions for stability testing of pharmaceuticals in hot and humid regions. Drug Dev Ind Pharm, 2007;33:393–401.
   PubMed Web of Science ®Google Scholar
• Buttini F, Colombo P, Rossi A, Sonvico F, Colombo G. Particles and powders: tools of innnovation for non-invasive drug administration. J Control Release, 2012;161:693–702.
   PubMed Web of Science ®Google Scholar
• Davis GF. Adverse effects of corticosteroids: II. Systemic. Clin Dermatol, 1986;4:161–9.
   PubMedGoogle Scholar
• de la Lastra CA, Villegas I. Resveratrol as an anti-inflammatory and anti-aging agent: Mechanisms and clinical implications. Mol Nutr Food Res, 2005;49:405–30.
   PubMed Web of Science ®Google Scholar
• Delmas D, Aires V, Limagne E, Dutartre P, Mazué F, Ghiringhelli F, Latruffe N. Transport, stability, and biological activity of resveratrol. Ann N Y Acad Sci, 2011;1215:48–59.
   PubMed Web of Science ®Google Scholar
• Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: Clinical and therapeutic implications. Allergy, 2008;63:1292–300.
   PubMed Web of Science ®Google Scholar
• FDA, 2003. Guidance for industry. Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action. Available at: www.fda.gov.
   Google Scholar
• Gallant C, Kenny P. Oral glucocorticoids and their complications. A review. J Am Acad Dermatol, 1986;14:161–77.
   PubMed Web of Science ®Google Scholar
• Jaspart S, Piel G, Delattre L, Evrard B. Solid lipid microparticles: Formulation, preparation, characterisation, drug release and applications. Expert Opin Drug Deliv, 2005;2:75–87.
   PubMedGoogle Scholar
• Karaki M, Akiyama K, Mori N. Efficacy of intranasal steroid spray (mometasone furoate) on treatment of patients with seasonal allergic rhinitis: Comparison with oral corticosteroids. Auris Nasus Larynx, 2013;40:277–81.
   PubMed Web of Science ®Google Scholar
• Kim SW, Kim DW, Khalmuratova R, Kim JH, Jung MH, Chang DY, Shin EC, Lee HK, Shin HW, Rhee CS, et al. Resveratrol prevents development of eosinophilic rhinosinusitis with nasal polyps in a mouse model. Allergy Eur J Allergy Clin Immunol, 2013;68:862–9.
   Web of Science ®Google Scholar
• Kippax P, Suman J, Williams G. Understanding the requirements for effective nasal drug delivery. Pharm Technol Europe, 2010;9:58–65.
   Google Scholar
• Lund VJ. Impact of chronic rhinosinusitis on quality of life and health care expenditure. Clin Allergy Immunol, 2007;20:15–24.
   PubMedGoogle Scholar
• Miraglia Del Giudice M, Maiello N, Capristo C, Alterio E, Capasso M, Perrone L, Ciprandi G. Resveratrol plus carboxymethyl-β-glucan reduces nasal symptoms in children with pollen-induced allergic rhinitis. Curr Med Res Opin, 2014;30:1931–5.
   PubMed Web of Science ®Google Scholar
• Neves R, Lucio M, Lima LCJ, Reis S. Resveratrol in medicinal chemistry: A critical review of its pharmacokinetics, drug-delivery and membrane interactions. Curr Med Chem, 2012;19:1663–81.
   PubMed Web of Science ®Google Scholar
• Ooi EH, Wormald PJ, Tan LW. Innate immunity in the paranasal sinuses a review of nasal host defence. Am J Rhinol, 2008;22:13–19.
   PubMedGoogle Scholar
• Palamara AT, Nencioni L, Aquilano K, De Chiara G, Hernandez L, Cozzolino F, Ciriolo MR, Garaci E. Inhibition of influenza A virus replication by resveratrol. J Infect Dis, 2005;191:1719–29.
   PubMed Web of Science ®Google Scholar
• Pozzoli M, Sonvico F, Ong HX, Bebawy M, Young PM. Optimization of RPMI 2650 cells as a model for nasal mucosa. Respirat Drug Deliv, 2014;739–42.
   Google Scholar
• Pozzoli M, Cattaneo S, Zhu B, Traini D, Young P, Sonvico F. Validation of a novel apparatus for deposition studies of nasal products. Respirat Drug Deliv Europe, 2015;537–42.
   Google Scholar
• Pozzoli M, Ong HX, Morgan L, Sukkar Traini D, Young PM, Sonvico F. Application of RPMI 2650 nasal cell model to a 3D printed apparatus for the testing of drug deposition and permeation of nasal products. Eur J Pharm Biopharm, 2016;107:223–33.
   PubMed Web of Science ®Google Scholar
• Sanna V, Kirschvink N, Gustin P, Gavini E, Roland I, Delattre L, Evrard B. Preparation and in vivo toxicity study of solid lipid microparticles as carrier for pulmonary administration. AAPS PharmSciTech, 2004;5:17–23.
   Web of Science ®Google Scholar
• Scalia S, Tursilli R, Sala N, Iannuccelli V. Encapsulation in lipospheres of the complex between butylmethoxydibenzoylmethane and hydroxypropyl-β-cyclodextrin. Int J Pharm, 2006;320:79–85.
   PubMed Web of Science ®Google Scholar
• Scalia S, Salama R, Young P, Traini D. Preparation and in vitro evaluation of salbutamol-loaded lipid microparticles for sustained release pulmonary delivery. J Microencapsul, 2012;29:225–33.
   PubMed Web of Science ®Google Scholar
• Scalia S, Haghi M, Losi V, Trotta V, Young PM, Traini D. Quercetin solid lipid microparticles: A flavonoid for inhalation lung delivery. Eur J Pharm Sci, 2013a;49:278–85.
   PubMed Web of Science ®Google Scholar
• Scalia S, Trotta V, Traini D, Young PM, Sticozzi C, Cervellati F, Valacchi G. Incorporation of quercetin in respirable lipid microparticles: Effect on stability and cellular uptake on A549 pulmonary alveolar epithelial cells. Colloids Surf B Biointerfaces, 2013b;112:322–9.
   PubMed Web of Science ®Google Scholar
• Scalia S, Young PM, Traini D. Solid lipid microparticles as an approach to drug delivery. Expert Opin Drug Deliv, 2015a;12:583–99.
   PubMed Web of Science ®Google Scholar
• Scalia S, Trotta V, Iannuccelli V, Bianchi A. Enhancement of in vivo human skin penetration of resveratrol by chitosan-coated lipid microparticles. Colloids Surf B Biointerfaces, 2015b;135:42–9.
   PubMed Web of Science ®Google Scholar
• Sezer AD, Cevher E. Topical drug delivery using chitosan nano- and microparticles. Expert Opin Drug Deliv, 2012;9:1129–46.
   PubMed Web of Science ®Google Scholar
• Stephanie AJ, Rakhi T, Jie H. A systematic review of the use of intranasal steroids in the treatment of chronic rhinosinusitis. Otolaryngology, 2008;139:340–7.
   Google Scholar
• Tran NP, Vickery J, Blaiss MS. Management of rhinitis: Allergic and non-allergic. Allergy Asthma Immunol Res, 2011;3:148–56.
   PubMed Web of Science ®Google Scholar
• Trotta V, Lee WH, Loo CY, Haghi M, Young PM, Scalia S, Traini D. In vitro biological activity of resveratrol using a novel inhalable resveratrol spray-dried formulation. Int J Pharm, 2015;491:190–7.
   PubMed Web of Science ®Google Scholar
• Zhang S, Blount AC, McNicholas CM, Skinner DF, Chestnut M, Kappes JC, Sorscher EJ, Woodworth BA. Resveratrol enhances airway surface liquid depth in sinonasal epithelium by increasing cystic fibrosis transmembrane conductance regulator open probability. PLoS One, 2013;8:1–9.
   Web of Science ®Google Scholar